Your browser is no longer supported. Please, upgrade your browser.
Penumbra, Inc.
Index- P/E248.94 EPS (ttm)0.90 Insider Own0.40% Shs Outstand36.62M Perf Week-13.71%
Market Cap8.68B Forward P/E157.48 EPS next Y1.42 Insider Trans-46.71% Shs Float35.71M Perf Month-10.97%
Income33.60M PEG10.78 EPS next Q0.22 Inst Own81.00% Short Float4.86% Perf Quarter-18.44%
Sales710.50M P/S12.22 EPS this Y-132.90% Inst Trans0.16% Short Ratio10.42 Perf Half Y-16.41%
Book/sh18.87 P/B11.83 EPS next Y72.51% ROA3.80% Target Price323.17 Perf Year-9.12%
Cash/sh6.87 P/C32.52 EPS next 5Y23.10% ROE5.00% 52W Range218.00 - 320.00 Perf YTD-22.28%
Dividend- P/FCF- EPS past 5Y-50.60% ROI-3.00% 52W High-30.22% Beta0.39
Dividend %- Quick Ratio3.50 Sales past 5Y24.70% Gross Margin62.50% 52W Low2.43% ATR11.68
Employees3300 Current Ratio5.80 Sales Q/Q25.80% Oper. Margin4.30% RSI (14)33.55 Volatility5.41% 4.45%
OptionableYes Debt/Eq0.04 EPS Q/Q196.60% Profit Margin4.70% Rel Volume1.15 Prev Close223.30
ShortableYes LT Debt/Eq0.04 EarningsNov 03 AMC Payout0.00% Avg Volume166.64K Price223.30
Recom1.40 SMA20-14.16% SMA50-13.21% SMA200-16.47% Volume0 Change0.00%
Sep-16-21Initiated Truist Buy $350
Jun-04-21Upgrade BTIG Research Neutral → Buy $291
Dec-16-20Downgrade BTIG Research Buy → Neutral
Oct-07-20Resumed Canaccord Genuity Buy $253
Sep-29-20Initiated BTIG Research Buy $233
Sep-08-20Downgrade BofA Securities Buy → Neutral
Mar-05-20Initiated Citigroup Buy $200
Jun-13-19Reiterated BofA/Merrill Buy $150 → $180
May-30-19Upgrade JP Morgan Neutral → Overweight
May-21-19Initiated William Blair Outperform
Oct-29-18Resumed BofA/Merrill Buy $36
Oct-08-18Initiated RBC Capital Mkts Outperform $174
Feb-21-18Initiated William Blair Outperform
Jan-02-18Downgrade JP Morgan Overweight → Neutral
Nov-30-15Reiterated Canaccord Genuity Buy $50 → $58
Oct-13-15Initiated Wells Fargo Outperform
Jan-13-22 11:51PM  
Dec-27-21 08:55AM  
Dec-23-21 12:38PM  
Dec-22-21 04:05PM  
Dec-16-21 10:15AM  
Dec-09-21 12:42PM  
Dec-03-21 09:51AM  
Nov-11-21 11:23AM  
Nov-10-21 09:08AM  
Nov-05-21 01:36PM  
Nov-03-21 11:00PM  
Oct-27-21 03:03PM  
Oct-18-21 04:58AM  
Oct-06-21 04:05PM  
Sep-29-21 06:22PM  
Sep-27-21 01:13PM  
Sep-22-21 01:45PM  
Sep-21-21 04:52PM  
Sep-20-21 12:43AM  
Sep-15-21 07:10PM  
Sep-13-21 09:30AM  
Sep-09-21 06:55PM  
Sep-07-21 09:30PM  
Sep-05-21 06:26AM  
Sep-02-21 08:33PM  
Aug-31-21 08:08PM  
Aug-30-21 09:45PM  
Aug-27-21 01:51PM  
Aug-26-21 04:05PM  
Aug-11-21 06:13AM  
Aug-10-21 09:00AM  
Aug-09-21 06:05PM  
Aug-02-21 03:01PM  
Jul-28-21 04:05PM  
Jul-13-21 09:07AM  
Jul-12-21 04:05PM  
Jun-25-21 11:41AM  
Jun-23-21 09:00AM  
May-18-21 04:05PM  
May-07-21 02:24AM  
May-04-21 10:30PM  
Apr-30-21 06:12AM  
Apr-27-21 04:05PM  
Apr-19-21 11:28AM  
Apr-13-21 04:05PM  
Mar-30-21 07:44AM  
Mar-29-21 03:54PM  
Mar-23-21 11:30AM  
Mar-19-21 01:06PM  
Mar-18-21 08:00AM  
Mar-16-21 08:30PM  
Mar-15-21 11:19PM  
Mar-14-21 10:50PM  
Mar-13-21 07:15PM  
Mar-12-21 10:50PM  
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elsesser AdamCEO and PresidentJan 11Option Exercise7.7514,500112,37514,500Jan 13 07:36 PM
Elsesser AdamCEO and PresidentJan 11Sale253.3414,5003,673,4890Jan 13 07:36 PM
Wilder ThomasDirectorJan 04Sale283.998022,71954Jan 05 07:34 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryJan 03Option Exercise22.043,25071,63060,874Jan 05 07:41 PM
Sarna SurbhiDirectorJan 03Sale285.349426,8221,325Jan 05 07:46 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryJan 03Sale281.573,250915,09357,624Jan 05 07:41 PM
Grewal HarpreetDirectorJan 03Sale285.34634180,90610,730Jan 05 07:37 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 28Option Exercise22.044,800105,79257,624Dec 30 07:50 PM
Elsesser AdamCEO and PresidentDec 13Option Exercise7.7514,500112,37514,500Dec 15 07:36 PM
Elsesser AdamCEO and PresidentDec 13Sale248.9514,5003,609,7150Dec 15 07:36 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 01Option Exercise22.041,75038,57054,574Dec 03 07:53 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 01Sale246.971,750432,19252,824Dec 03 07:53 PM
O'Rourke BridgetDirectorNov 15Sale265.366517,2483,338Nov 17 07:52 PM
Elsesser AdamCEO and PresidentNov 11Option Exercise7.7514,500112,37514,500Nov 15 07:39 PM
Elsesser AdamCEO and PresidentNov 11Sale264.1814,5003,830,6280Nov 15 07:39 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryNov 08Option Exercise22.042,50055,10053,824Nov 10 07:41 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryNov 08Sale279.212,500698,03651,324Nov 10 07:41 PM
Sarna SurbhiDirectorNov 01Sale278.06907252,2001,419Nov 02 07:47 PM
O'Rourke BridgetDirectorOct 14Sale266.436517,3183,403Oct 15 07:38 PM
Elsesser AdamCEO and PresidentOct 11Option Exercise7.7514,500112,37514,500Oct 14 06:04 AM
Elsesser AdamCEO and PresidentOct 11Sale254.6014,5003,691,7120Oct 14 06:04 AM
Rothman LynnEVP and Chief Business OfficerOct 01Option Exercise22.045,300116,81237,937Oct 05 08:17 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryOct 01Option Exercise22.042,50055,10053,824Oct 05 08:18 PM
Grewal HarpreetDirectorOct 01Sale267.06634169,31611,364Oct 05 08:17 PM
Pray James RobertPresident, InternationalOct 01Sale261.735,0001,308,629408,431Oct 05 08:18 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryOct 01Sale261.632,500654,07451,324Oct 05 08:18 PM
Rothman LynnEVP and Chief Business OfficerOct 01Sale261.705,3001,387,00832,637Oct 05 08:17 PM
Wilder ThomasDirectorOct 01Sale267.068021,365188Oct 05 08:17 PM
Elsesser AdamCEO and PresidentSep 13Option Exercise7.7514,500112,37514,500Sep 15 09:07 PM
Elsesser AdamCEO and PresidentSep 13Sale280.4214,5004,066,0370Sep 15 09:07 PM
Roberts JohannaEVP, Gen. Counsel & SecretarySep 01Option Exercise22.042,50055,10053,824Sep 03 08:27 PM
Rothman LynnEVP and Chief Business OfficerSep 01Option Exercise22.045,300116,81237,937Sep 03 08:26 PM
Rothman LynnEVP and Chief Business OfficerSep 01Sale271.815,3001,440,61632,637Sep 03 08:26 PM
Pray James RobertPresident, InternationalSep 01Sale271.775,0001,358,848413,431Sep 03 08:26 PM
Roberts JohannaEVP, Gen. Counsel & SecretarySep 01Sale272.022,500680,04151,324Sep 03 08:27 PM
Grewal HarpreetDirectorAug 31Sale271.21732198,52611,998Sep 02 07:19 PM
O'Rourke BridgetDirectorAug 16Sale255.606516,6143,468Aug 17 07:42 PM
Elsesser AdamCEO and PresidentAug 11Option Exercise7.7514,500112,37514,500Aug 12 08:02 PM
Elsesser AdamCEO and PresidentAug 11Sale251.2414,5003,642,9150Aug 12 08:02 PM
Rothman LynnEVP and Chief Business OfficerAug 10Option Exercise22.045,300116,81237,937Aug 12 08:03 PM
Pray James RobertPresident, InternationalAug 10Sale260.795,0001,303,932418,431Aug 12 08:02 PM
Rothman LynnEVP and Chief Business OfficerAug 10Sale265.955,3001,409,52332,637Aug 12 08:03 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryAug 09Option Exercise22.042,50055,10053,824Aug 11 07:13 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryAug 09Sale263.142,500657,85051,324Aug 11 07:13 PM
O'Rourke BridgetDirectorJul 14Sale266.456517,3193,533Jul 16 09:52 PM
Wilder ThomasDirectorJul 12Sale275.0916144,289374Jul 14 07:25 PM
Rothman LynnEVP and Chief Business OfficerMay 07Option Exercise3.9810,15540,41732,637May 11 07:50 PM
Bose AraniChief InnovatorFeb 01Sale259.4310,0002,594,271530,662Feb 03 07:22 PM
Pray James RobertPresident, InternationalFeb 01Sale259.645,0001,298,199423,431Feb 03 07:22 PM
Bose AraniChief InnovatorJan 25Sale255.8110,0002,558,100540,662Jan 27 06:58 PM